Products - Ovarian cancer | Topic | NICE

Showing 12 products

Date | Sort by Title

Status: In developmentRemove ‘Status: In development’ filter

Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (including review of TA381) [ID1296]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
15 January 2020
Ovarian (epithelial), fallopian and peritoneal cancer - pazopanib (maintenance) [ID545]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ovarian cancer - vintafolide (with pegylated liposomal doxorubicin) [ID564]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cediranib for treating relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer [ID790]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ovarian, fallopian tube and peritoneal cancer - rucaparib [ID1184]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lurbinectidin for treating advanced platinum-resistant ovarian cancer ID1340
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Avelumab for previously treated platinum-resistant ovarian cancer ID1497
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Veliparib with carboplatin and paclitaxel for untreated epithelial ovarian, fallopian tube or primary peritoneal cancer ID1561
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Olaparib with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer [ID1652]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Niraparib for maintenance treatment of platinum-sensitive ovarian, fallopian tube and peritoneal cancer after response to 1 course of platinum-based chemotherapy [ID1680]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC